1. Home
  2. MCD vs GILD Comparison

MCD vs GILD Comparison

Compare MCD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MCD

McDonald's Corporation

HOLD

Current Price

$331.21

Market Cap

233.3B

ML Signal

HOLD

Logo Gilead Sciences Inc.

GILD

Gilead Sciences Inc.

HOLD

Current Price

$147.96

Market Cap

187.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCD
GILD
Founded
1940
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
233.3B
187.5B
IPO Year
1995
2000

Fundamental Metrics

Financial Performance
Metric
MCD
GILD
Price
$331.21
$147.96
Analyst Decision
Buy
Strong Buy
Analyst Count
26
18
Target Price
$340.12
$143.50
AVG Volume (30 Days)
3.3M
6.6M
Earning Date
05-14-2026
05-13-2026
Dividend Yield
2.22%
2.19%
EPS Growth
4.92
1684.21
EPS
11.95
6.78
Revenue
$26,885,000,000.00
$24,689,000,000.00
Revenue This Year
$8.35
$4.68
Revenue Next Year
$5.73
$5.81
P/E Ratio
$28.06
$22.14
Revenue Growth
3.72
9.98
52 Week Low
$283.47
$95.30
52 Week High
$341.75
$157.29

Technical Indicators

Market Signals
Indicator
MCD
GILD
Relative Strength Index (RSI) 56.88 54.35
Support Level $295.03 $108.90
Resistance Level $335.67 $157.29
Average True Range (ATR) 5.94 4.15
MACD -0.03 -1.31
Stochastic Oscillator 51.20 34.29

Price Performance

Historical Comparison
MCD
GILD

About MCD McDonald's Corporation

McDonald's is the world's largest restaurant brand, with nearly $131 billion in systemwide sales across more than 44,000 restaurants and over 100 markets. The quick-service chain built its early reputation on speed, consistency, and affordable hamburgers, and today its global menu spans burgers, chicken, breakfast, and beverages that have helped popularize American fast-food cuisine worldwide. The firm derives the bulk of its revenue from franchise royalties and rent (about 61%), with the remainder stemming from company-operated restaurants across three segments: the United States (41% of systemwide sales), international operated markets (34%), and international developmental/licensed markets (25%).

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Share on Social Networks: